1. 2009
2. Published

   Impact of the abolition of the prescription charge in Wales.

   Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009, p. O41.

   Research output: Contribution to conference › Paper

3. Published

   The economics of evergreening.

   Hughes, D. & Hughes, D. A., 1 Jan 2009.

   Research output: Contribution to conference › Paper

4. 2008
5. Published

   Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens

   Hughes, D. & Hughes, D. A., 1 Dec 2008, In: British Journal of Clinical Pharmacology. 65, 6, p. 871-878

   Research output: Contribution to journal › Article › peer-review

6. Published

   Impact of the abolition of the prescription charge in Wales

   Hughes, D. & Hughes, D. A., 1 Nov 2008.

   Research output: Contribution to conference › Paper

7. Published

   Methodological Issues in the literature on costs of non-compliance in chronic diseases.

   Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008, In: Value in Health. 11, 6, p. A571-A572

   Research output: Contribution to journal › Article › peer-review

8. Published

   Methodological issues in the literature on costs of non-compliance in chronic diseases

   Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008.

   Research output: Contribution to conference › Paper

9. Published

   The all wales medicines strategy group: assessments and appraisals

   Hughes, D. & Hughes, D. A., 1 Nov 2008.

   Research output: Contribution to conference › Paper

10. Published

    Medicines concordance and game theory.

    Hughes, D. & Hughes, D. A., 1 Oct 2008, In: British Journal of Clinical Pharmacology. 66, 4, p. 577

    Research output: Contribution to journal › Article › peer-review

11. Published

    Economic considerations for pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Jun 2008.

    Research output: Contribution to conference › Paper

12. Published

    Costs of non-compliance to antipsychotic medications among patients with schizophrenia.

    Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 May 2008.

    Research output: Contribution to conference › Paper

13. Published

    The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 May 2008.

    Research output: Contribution to conference › Paper

14. Published

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Apr 2008.

    Research output: Contribution to conference › Paper

15. Published

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Apr 2008.

    Research output: Contribution to conference › Paper

16. Published

    Effects of the abolition of prescription charges in Wales: A preliminary analysis

    Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Apr 2008.

    Research output: Contribution to conference › Paper

17. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment

    Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Mar 2008

    Research output: Non-textual form › Web publication/site

18. Published

    Statistical comments are unfounded.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Mar 2008, In: Value in Health. 11, 2, p. 346

    Research output: Contribution to journal › Article › peer-review

19. Published

    The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

    Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Mar 2008.

    Research output: Contribution to conference › Paper

20. Published

    Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Feb 2008.

    Research output: Contribution to conference › Paper

21. Published

    From efficacy to cost-effectiveness: Impact of patient compliance

    Hughes, D. & Hughes, D. A., 1 Feb 2008.

    Research output: Contribution to conference › Paper

22. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

23. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

24. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

25. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

26. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

27. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report